The Onychomycosis market report also offers comprehensive insights into the Onychomycosis market size, share, Onychomycosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Onychomycosis market size growth forward.
Some of the key highlights from the Onychomycosis Market Insights Report:
-
Several key pharmaceutical companies, including Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others, are developing novel products to improve the Onychomycosis treatment outlook.
-
In June 2014, the FDA approved JUBLIA for treating toenail onychomycosis caused by *Trichophyton rubrum* or *Trichophyton mentagrophytes*.
-
In July 2014, CLENAFIN (efinaconazole) received approval from the PMDA for the treatment of onychomycosis in Japan.
-
In 2023, there were approximately 83,553 thousand prevalent cases of Onychomycosis across the 7MM. The rise in cases can be attributed to factors such as aging populations, lifestyle habits like poor foot hygiene and tight footwear, and increased exposure to communal areas such as swimming pools, which heighten susceptibility.
-
According to DelveInsight’s analysts, in 2023, distal subungual onychomycosis was the most common subtype of Onychomycosis in the US, accounting for approximately 90% of cases. There were 6,034 thousand cases of this subtype in 2023, with projections indicating changes throughout the study period (2020-2034).
-
Among the EU4 and the UK, France had the highest number of diagnosed prevalent Onychomycosis cases, with about 2,046 thousand cases in 2023, and these numbers are expected to change during the study period (2020-2034).
-
Onychomycosis is typically categorized into mild (25% or less nail involvement), moderate (26–74% involvement), and severe (more than 75% involvement). In 2023, Spain had 70,300 mild, 101,630 moderate, and 82,781 severe cases. DelveInsight’s analysis predicts an increase in these cases during the forecast period (2024-2034).
-
Among the approved treatments for Onychomycosis, Topical Pharmacotherapy is projected to hold the largest market share in the US by 2034.
-
With the anticipated approval of new therapies during the forecast period (2024–2034), the Onychomycosis therapeutic market is expected to grow significantly at a strong CAGR. This growth will likely be driven by enhanced diagnostic methods, the introduction of new products, and ongoing research into pharmaceutical treatments.
-
As per DelveInsight analysis, the Onychomycosis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Onychomycosis Market Landscape
Onychomycosis Overview
Onychomycosis, a fungal infection of the nail, is the most prevalent nail infection globally, leading to discoloration and thickening of the affected nail. Initially believed to be primarily caused by dermatophytes, recent studies have shown that mixed infections and those caused by non-dermatophyte molds (NDMs) are more common, particularly in warmer climates. When caused by dermatophytes, onychomycosis is referred to as tinea unguium. The term onychomycosis includes not only dermatophyte infections but also those caused by yeasts and saprophytic molds. While onychomycosis can affect both fingernails and toenails, toenail infections are far more common. An abnormal nail not caused by a fungal infection is termed a dystrophic nail.
Onychomycosis is traditionally classified into subtypes based on how the fungus invades the nail, which helps guide treatment. Distal subungual onychomycosis (DSO) is the most common subtype and occurs when the fungus invades the distal part of the nail plate. In superficial white onychomycosis (SWO), the fungus affects the surface layers of the nail plate. Proximal subungual onychomycosis (PSO) happens when the infection begins at the undersurface of the proximal nail fold and spreads distally. Endonyx onychomycosis (EO) involves the fungus invading the nail plate without affecting the nail bed. Total dystrophic onychomycosis (TDO) represents advanced onychomycosis and may follow any of the other subtypes. Secondary onychomycosis (SO) is a non-fungal nail condition (e.g., psoriasis) that becomes infected with a secondary fungal infection, showing characteristics of both fungal and non-fungal nail disorders.
Do you know the treatment paradigms for different countries? Download our Onychomycosis Market Sample Report
Onychomycosis Epidemiology Insights
-
In 2023, the total number of prevalent onychomycosis cases in the US was approximately 37,250 thousand. This figure is expected to undergo significant changes by 2034.
-
In Germany, during 2023, moderate onychomycosis cases were the most common, with around 726 thousand reported. These numbers are anticipated to vary throughout the forecast period from 2024 to 2034.
Onychomycosis Epidemiology Segmentation
DelveInsight’s Onychomycosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Onychomycosis historical patient pools and forecasted Onychomycosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Onychomycosis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Onychomycosis Prevalence
-
Age-Specific Onychomycosis Prevalence
-
Gender-Specific Onychomycosis Prevalence
-
Diagnosed and Treatable Cases of Onychomycosis
Visit for more @ Onychomycosis Epidemiological Insights
Onychomycosis Market Outlook
Onychomycosis is mainly a fungal infection of the nail bed, commonly known as ‘toenail fungus’ since toenail infections account for the majority of cases. Toenail issues are among the most common foot problems prompting adults to seek both over-the-counter treatments and professional care. The infection usually starts as a small white or yellow spot beneath the nail plate, leading to discoloration, thickening, and splitting of the nail. It is estimated that onychomycosis affects about 3% of the general adult population, with approximately 20% of individuals aged 40 to 60 years affected.
The current treatment options are typically categorized by their method of administration: Systemic (oral) and Topical medications.
Despite numerous attempts to develop effective treatments for toenail fungus, the few FDA/EMA/PMDA-approved products currently available remain suboptimal for two key reasons. Topical treatments often have low cure rates and poor efficacy since they cannot penetrate the nail plate adequately to reach the infected nail bed, and they may require nail debridement before application. On the other hand, the leading oral medication, terbinafine, must be taken daily for three months, and its systemic presence can lead to adverse effects. Both treatment types have low cure rates, with hepatotoxicity being a common side effect from prolonged oral use. Patients taking terbinafine must undergo regular liver function tests to monitor potential damage.
Onychomycosis Marketed Drugs
-
KERYDIN (tavaborole): Pfizer
-
JUBLIA/CLENAFIN (efinaconazole): Bausch Health
Onychomycosis Emerging Drugs
-
BB2603: Blueberry Therapeutics
-
VT-1161: Mycovia Pharmaceuticals
Onychomycosis Key Companies
-
Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others
For more information, visit Onychomycosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Onychomycosis Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Onychomycosis, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Onychomycosis epidemiology in the 7MM
-
Onychomycosis marketed and emerging therapies
-
Onychomycosis companies
-
Onychomycosis market drivers and barriers
Table of Contents:
1 Onychomycosis Market Key Comprehensive Insights
2 Onychomycosis Market Report Introduction
3 Competitive Intelligence Analysis for Onychomycosis
4 Onychomycosis Market Analysis Overview at a Glance
5 Executive Summary of Onychomycosis
6 Onychomycosis Epidemiology and Market Methodology
7 Onychomycosis Epidemiology and Patient Population
8 Onychomycosis Patient Journey
9 Onychomycosis Treatment Algorithm, Onychomycosis Current Treatment, and Medical Practices
10 Key Endpoints in Onychomycosis Clinical Trials
11 Onychomycosis Marketed Therapies
12 Onychomycosis Emerging Therapies
13 Onychomycosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Onychomycosis
16 Onychomycosis Market Key Opinion Leaders Reviews
18 Onychomycosis Market Drivers
19 Onychomycosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Onychomycosis Epidemiology 2034
DelveInsight’s “Onychomycosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Onychomycosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Onychomycosis Pipeline 2024
“Onychomycosis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onychomycosis market. A detailed picture of the Onychomycosis pipeline landscape is provided, which includes the disease overview and Onychomycosis treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/